Dorlo T P C, Eggelte T A, Beijnen J H, de Vries P J
Academisch Medisch Centrum/Universiteit van Amsterdam, afd. Inwendige Geneeskunde, onderafd. Infectieziekten, Tropische Geneeskunde en Aids, Meibergdreef 9, 1105 AZ Amsterdam.
Ned Tijdschr Geneeskd. 2006 Dec 9;150(49):2697-701.
There is a need for a safe and effective oral treatment for cutaneous and visceral leishmaniasis. Miltefosine is the first oral drug that is efficacious against different forms ofleishmaniasis, however it is not equally effective against all Leishmania species. Miltefosine is an alkylphosphocholine, originally developed for the treatment of cancer. The mechanism of action is probably based on interference with the synthesis and degradation of parasitic membrane lipids. Little is known about the pharmacokinetics ofmiltefosine; an important characteristic is its long elimination half-life of seven days or longer. The most frequent adverse effects are of gastrointestinal origin. Miltefosine should not be used during pregnancy. Over thirty leishmaniasis patients have already been treated with miltefosine in the Netherlands.
对于皮肤利什曼病和内脏利什曼病,需要一种安全有效的口服治疗方法。米替福新是第一种对不同形式的利什曼病有效的口服药物,然而它对所有利什曼原虫物种的效果并不相同。米替福新是一种烷基磷胆碱,最初是为治疗癌症而开发的。其作用机制可能是基于干扰寄生虫膜脂的合成和降解。关于米替福新的药代动力学知之甚少;一个重要特征是其长达七天或更长时间的消除半衰期。最常见的不良反应源于胃肠道。怀孕期间不应使用米替福新。在荷兰,已有三十多名利什曼病患者接受了米替福新治疗。